ASCVD
ASCVD company profile
Latest price
As of — · Market data by Massive
Market cap
—
Volume
—
Previous close
—
Day range
—
Listed
—
Coverage
6 articles
Price performance
Recent trading
Newsroom
Latest ASCVD coverage
100 years of lifesaving work and counting: Happy Birthday to the American Heart Association
[ad_1] Embargoed until 1 p.m. CT/2 p.m. ET Monday, Jan. 8, 2024 (NewMediaWire) – January 08, 2024 – DALLAS — From humble beginnings as a small professional health society formed by six cardiologists in Chicago in 1924, the American Heart Association has emerged as the nation’s oldest and largest voluntary organization dedicated to fighting heart
$150,000 awarded to research race in clinical algorithms
[ad_1] (NewMediaWire) – August 08, 2023 – DALLAS — As part of a focused effort to assess current cardiovascular treatment algorithms for racial bias, the American Heart Association, the single largest non-government supporter of heart and brain health research in the U.S., is funding three new scientific research projects at $50,000 each. Clinic
New research project aims to set standardized approach to lipoprotein(a) management
[ad_1] (NewMediaWire) – March 24, 2023 – DALLAS — High levels of lipoprotein(a) [Lp(a)] are an independent, predominantly inherited and causal risk factor for cardiovascular disease, the leading cause of death and disability worldwide, according to a recent American Heart Association scientific statement. It is estimated that 1 in 5 Americans hav
New effort to standardize cardiovascular care in Mexico, address gaps in care
[ad_1] (NewMediaWire) – June 02, 2022 – DALLAS and MEXICO CITY — In Mexico, 56.1% of adults have high levels of LDL-C or bad cholesterol[1], considered the main risk factor for cardiovascular disease and cause of atherosclerotic cardiovascular disease (ASCVD), a buildup of fats, cholesterol and other substances inside the arteries and on their wa
New initiative to help people with high cholesterol and associated cardiovascular disease
[ad_1] (NewMediaWire) – July 16, 2021 – DALLAS – In the United States, nearly half of all adults (56 million or 48.6%) over 40 years of age have blood cholesterol levels that put them at risk for atherosclerotic cardiovascular disease (ASCVD), increasing the possibility of heart disease and stroke, as noted in the most recent ...
Gender-affirming hormone therapy may not increase CVD risk for transgender adolescents
[ad_1] Research Highlights: Before receiving gender-affirming hormone therapy, transgender adolescents are more likely to have at least one atherosclerotic cardiovascular disease (ASCVD) risk factor compared to cisgender (same gender as at birth) adolescents. After one year of gender-affirming hormone therapy, fewer adolescent transgender females had a